These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 9849050)

  • 21. Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation.
    Dahlén E; Hedlund G; Dawe K
    J Immunol; 2000 Mar; 164(5):2444-56. PubMed ID: 10679081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Costimulatory molecules in autoimmunity: role of CD28/CTLA4-CD80/CD86].
    Nakajima A; Azuma M
    Nihon Rinsho; 1997 Jun; 55(6):1419-24. PubMed ID: 9200926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD28/B7 costimulation: a review.
    Greenfield EA; Nguyen KA; Kuchroo VK
    Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo.
    Metzler B; Burkhart C; Wraith DC
    Int Immunol; 1999 May; 11(5):667-75. PubMed ID: 10330272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
    Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
    Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
    Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
    J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CTLA-4 is a second receptor for the B cell activation antigen B7.
    Linsley PS; Brady W; Urnes M; Grosmaire LS; Damle NK; Ledbetter JA
    J Exp Med; 1991 Sep; 174(3):561-9. PubMed ID: 1714933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
    Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
    J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
    McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
    Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD28/CTLA-4 and CD80/CD86 families: signaling and function.
    Slavik JM; Hutchcroft JE; Bierer BE
    Immunol Res; 1999; 19(1):1-24. PubMed ID: 10374692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absence of B7-dependent responses in CD28-deficient mice.
    Green JM; Noel PJ; Sperling AI; Walunas TL; Gray GS; Bluestone JA; Thompson CB
    Immunity; 1994 Sep; 1(6):501-8. PubMed ID: 7534617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The complexity of the B7-CD28/CTLA-4 costimulatory pathway.
    Schweitzer AN; Sharpe AH
    Agents Actions Suppl; 1998; 49():33-43. PubMed ID: 9426826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.
    Boussiotis VA; Freeman GJ; Gribben JG; Daley J; Gray G; Nadler LM
    Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11059-63. PubMed ID: 7504293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.
    Schwartz RH
    Cell; 1992 Dec; 71(7):1065-8. PubMed ID: 1335362
    [No Abstract]   [Full Text] [Related]  

  • 35. CTLA-4Ig: uses and future directions.
    Ben-Shoshan M
    Recent Pat Inflamm Allergy Drug Discov; 2009 Jun; 3(2):132-42. PubMed ID: 19519590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies.
    Murata K; Dalakas MC
    Am J Pathol; 1999 Aug; 155(2):453-60. PubMed ID: 10433938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergy between cyclosporin A and a monoclonal antibody to B7 in blocking alloantigen-induced T-cell activation.
    Van Gool SW; Ceuppens JL; Walter H; de Boer M
    Blood; 1994 Jan; 83(1):176-83. PubMed ID: 7506079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costimulatory molecules and autoimmune thyroid diseases.
    Salmaso C; Olive D; Pesce G; Bagnasco M
    Autoimmunity; 2002 May; 35(3):159-67. PubMed ID: 12389640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.
    Freeman GJ; Lombard DB; Gimmi CD; Brod SA; Lee K; Laning JC; Hafler DA; Dorf ME; Gray GS; Reiser H
    J Immunol; 1992 Dec; 149(12):3795-801. PubMed ID: 1281186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.
    Greene JL; Leytze GM; Emswiler J; Peach R; Bajorath J; Cosand W; Linsley PS
    J Biol Chem; 1996 Oct; 271(43):26762-71. PubMed ID: 8900156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.